130,000 Shares in Versartis, Inc. (VSAR) Acquired by Jane Street Group LLC

Jane Street Group LLC bought a new stake in Versartis, Inc. (NASDAQ:VSAR) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 130,000 shares of the biopharmaceutical company’s stock, valued at approximately $319,000. Jane Street Group LLC owned about 0.36% of Versartis at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of VSAR. Artal Group S.A. grew its stake in shares of Versartis by 14.3% during the third quarter. Artal Group S.A. now owns 400,000 shares of the biopharmaceutical company’s stock worth $980,000 after acquiring an additional 50,000 shares during the last quarter. First Quadrant L P CA grew its stake in shares of Versartis by 1,253.8% during the third quarter. First Quadrant L P CA now owns 120,500 shares of the biopharmaceutical company’s stock worth $295,000 after acquiring an additional 111,599 shares during the last quarter. Lord Abbett & CO. LLC grew its stake in shares of Versartis by 26.5% during the second quarter. Lord Abbett & CO. LLC now owns 319,854 shares of the biopharmaceutical company’s stock worth $5,582,000 after acquiring an additional 66,977 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Versartis by 4.8% during the second quarter. The Manufacturers Life Insurance Company now owns 26,326 shares of the biopharmaceutical company’s stock worth $459,000 after acquiring an additional 1,204 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Versartis by 6.9% during the second quarter. State Street Corp now owns 556,718 shares of the biopharmaceutical company’s stock worth $9,716,000 after acquiring an additional 35,957 shares during the last quarter. Institutional investors own 49.18% of the company’s stock.

Shares of Versartis, Inc. (NASDAQ:VSAR) opened at $2.10 on Thursday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.52 and a current ratio of 1.52. Versartis, Inc. has a twelve month low of $1.60 and a twelve month high of $24.00.

Versartis (NASDAQ:VSAR) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.78). During the same period in the previous year, the business earned ($0.92) earnings per share. sell-side analysts predict that Versartis, Inc. will post -4.14 earnings per share for the current fiscal year.

In other news, Director Srinivas Akkaraju bought 513,872 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was purchased at an average price of $2.21 per share, with a total value of $1,135,657.12. Following the completion of the acquisition, the director now directly owns 14,955 shares of the company’s stock, valued at approximately $33,050.55. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of Versartis stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $3.29, for a total value of $7,007,700.00. The disclosure for this sale can be found here. Insiders have sold 2,132,769 shares of company stock valued at $7,014,761 in the last ninety days. Corporate insiders own 10.90% of the company’s stock.

A number of equities research analysts have recently weighed in on VSAR shares. Piper Jaffray Companies restated a “buy” rating and set a $26.00 price target on shares of Versartis in a research note on Friday, September 8th. Canaccord Genuity restated a “buy” rating and set a $9.00 price target (down previously from $28.00) on shares of Versartis in a research note on Friday, September 22nd. Cantor Fitzgerald set a $14.00 price target on Versartis and gave the stock a “buy” rating in a research note on Friday, October 27th. Morgan Stanley restated an “equal weight” rating and set a $4.00 price target (up previously from $3.00) on shares of Versartis in a research note on Friday, September 22nd. Finally, Barclays lowered Versartis from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $28.00 to $4.00 in a research note on Friday, September 22nd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $5.63.

WARNING: “130,000 Shares in Versartis, Inc. (VSAR) Acquired by Jane Street Group LLC” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.com-unik.info/2017/12/21/130000-shares-in-versartis-inc-vsar-acquired-by-jane-street-group-llc.html.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

What are top analysts saying about Versartis? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Versartis and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit